Log In
BCIQ
Print this Print this
 

fenfluramine (ZX008) (formerly Brabafen)

  Manage Alerts
Collapse Summary General Information
Company Zogenix Inc.
DescriptionOral solution of low-dose fenfluramine, a derivative of amphetamine that promotes the release of serotonin (5-HT) from neuronal storage vesicles and inhibits its reuptake
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationEpilepsy
Indication DetailsTreat Dravet syndrome
Regulatory Designation U.S. - Fast Track (Treat Dravet syndrome);
U.S. - Orphan Drug (Treat Dravet syndrome);
EU - Orphan Drug (Treat Dravet syndrome)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$130.0M

$20.0M

$50.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/27/2014

$130.0M

$20.0M

$50.0M

Get a free BioCentury trial today